All In Biotech

Drug Trial Radar · NCT03801889

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Multicenter, Open-label, 52 Week, Dose-escalation Study of SP 420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 2020

Primary completion

Sep 2022

Study completion Jan 2023

Sponsor

Lead sponsor
Abfero Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Jan 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

Conditions

  • Iron Overload
  • Beta-Thalassemia

Interventions

  • SP-420Drug

    Self-administered by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of treatment-emergent Adverse Events (AEs)Time frame: Week 24
  2. The incidence of treatment-emergent Adverse Events (AEs)Time frame: Week 52

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Toronto- University Health Network

    Toronto, Canada

  • American University of Beirut Medical Center

    Beirut, Lebanon

  • Siriraj Hospital

    Bangkok, Thailand

  • Ege University Hospital

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.